Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata listed "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Stage: Late-stage development company focused on ex vivo production of human cells for cell therapy. The company operates in one segment: research and product development.
Key Products: Tissue Repair Cells (TRCs) for bone grafting and the AastromReplicell System for cell production.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2004 | Nine Months Ended Mar 31, 2004 | Balance Sheet (Mar 31, 2004) |
|---|---|---|---|
| Total Revenues | $416,000 | $1,092,000 | - |
| Net Loss | $(2,500,000) | $(7,741,000) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.11) | - |
| Cash and Cash Equivalents | - | - | $10,426,000 |
| Total Assets | - | - | $12,171,000 |
| Total Liabilities | - | - | $545,000 |
| Accumulated Deficit | - | - | $(111,117,000) |
| Net Cash Used in Operating Activities | - | $(7,356,000) | - |
Note: The filing does not provide specific gross margin percentages. Revenue is primarily derived from grants ($972,000 for nine months) and research agreements.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased to $416,000 for the quarter (from $280,000 in 2003) and $1,092,000 for the nine months (from $669,000 in 2003). This was driven by a significant increase in grant revenues ($331,000 vs. $150,000 for the quarter) due to activity with DARPA and NIH.
- Product Sales Decline: Product sales and rentals decreased to $10,000 for the quarter (from $130,000) and $45,000 for the nine months (from $298,000), attributed to extended internal evaluations by potential customers.
- Expense Increases: Total costs and expenses rose to $2,944,000 for the quarter (from $2,412,000) and $8,946,000 for the nine months (from $7,614,000). Selling, general, and administrative (SG&A) expenses increased significantly due to expanded marketing in Europe and capital raising costs.
- Inventory Provision: The non-cash provision for obsolete inventory dropped to zero for the quarter (from $186,000) as the company had previously written down the carrying value of its AastromReplicell System inventory to zero.
- Net Loss: Net loss increased to $2,500,000 for the quarter (from $2,102,000) and $7,741,000 for the nine months (from $6,841,000), primarily due to higher operating expenses.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects available cash and recent financing to fund planned activities through the end of fiscal year 2005 (June 30, 2005). However, additional funding will be required to complete product development and commercialization.
- Recent Financing: In early April 2004 (subsequent to the period end), the company completed a registered direct offering of 8,000,000 shares for net proceeds of approximately $8,500,000.
- Operational Progress: The company initiated Phase I/II clinical trials for bone grafting in the U.S. and Europe. European clinical trials for dendritic cell products have faced delays due to new EU directives.
- Key Risks:
- Funding: Inability to raise additional capital could force delays or termination of R&D programs.
- Regulatory: Failure to obtain FDA or EU regulatory approvals for cell products or changes in regulatory classification of the AastromReplicell System.
- Commercialization: Lack of third-party reimbursement and competition from established medical device companies.
- Supply Chain: Reliance on third-party manufacturers for critical components and growth factors.
Investor Verification Checklist
- Verify the status and enrollment rates of the Phase I/II bone grafting clinical trials initiated in the U.S. and Europe.
- Confirm the impact of new EU directives on the timeline for dendritic cell clinical trials and sales in Europe.
- Assess the company's burn rate against the $10.4 million cash balance to validate the runway through fiscal 2005.
- Review the terms and dilution impact of the April 2004 registered direct offering and any subsequent financing activities.
- Monitor the progress of the strategic alliance with the Musculoskeletal Transplant Foundation (MTF).